Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2Phase 1/2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 16UNKNOWN 2OTHER_GOV 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Thoracic 1

Conditions

Breast Neoplasms 107Neoplasms 70Colorectal Neoplasms 51Uterine Cervical Neoplasms 41Prostatic Neoplasms 32Stomach Neoplasms 31Motor Activity 26Carcinoma, Hepatocellular 24Lung Neoplasms 22Rectal Neoplasms 21Colonic Neoplasms 19Head and Neck Neoplasms 18Pancreatic Neoplasms 17Brain Neoplasms 15Pain 14Polycystic Ovary Syndrome 13Recurrence 12Pain, Postoperative 11Lymphoma 11Esophageal Neoplasms 11Anxiety Disorders 11Ovarian Neoplasms 10Glioma 10Endometrial Neoplasms 10Thyroid Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Pilonidal Sinus 9Carcinoma, Non-Small-Cell Lung 9Papillomavirus Infections 8Hematologic Neoplasms 8

Interventions

aumolertinib 1aflutinib 1Pemetrexed 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × OTHER_GOV × Meningeal Carcinomatosis × Clear all
NCT06643000 2025-03-06

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Henan Cancer Hospital

Phase NA Recruiting
60 enrolled
CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT04778800 2021-08-31

A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)

Henan Cancer Hospital

Phase NA Unknown
60 enrolled
CNS

Brain Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡